Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADore)
J2T-DM-KGAE - ClinicalTrials.gov - NCT04250350
The study will assess the safety and efficacy of lebrikizumab in adolescent participants with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
Trial Summary
Age Range
12 - 17 yearsConditions the trial is for
Atopic Dermatitis (Eczema)What the trial is testing?
LebrikizumabCould I receive a Placebo?
NoEnrollment Goal
206Trial Dates
Feb 11, 2020 - Jun 22, 2022How long will I be in the trial?
The study will last about 52 weeks and may include up to 18 visits.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have atopic dermatitis that has been present for at least one year
Participants must have had an inadequate response to topical medications (medications applied to the skin)
Participants Must Not:
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Women must not be pregnant, breastfeeding or plan to become pregnant during the study
Lilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo